Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) Company Bio
Jazz Pharmaceuticals is an international biopharmaceutical company with a diverse portfolio of products and/or product candidates with a focus in the areas of sleep and hematology/oncology. The company was founded in 2003 and is based in Dublin, Ireland.
JAZZ Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Jazz Pharmaceuticals plc. To summarize, we found that Jazz Pharmaceuticals plc ranked in the 68th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 146.67% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Jazz Pharmaceuticals plc, consider:
Jazz Pharmaceuticals plc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
The weighted average cost of capital for the company is 7. This value is greater than only 17.02% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
NVO, DVA, FTLF, QDEL, and ABBV can be thought of as valuation peers to JAZZ, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Insider buying almost doubled last week with insiders purchasing $209.6 million of stock compared to $107.94 million in the week prior. Selling also increased with insiders selling $1.47 billion of stock last week compared to $1.33 billion in the week prior. Sell/Buy Ratio: The insider Sell/Buy ratio is calculated by...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it and its partners will present seven new abstracts at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting from May 29-June 2, 2020 and six abstracts at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. These new data from Jazz's expanding hematology and oncology portfolio and pipeline are focused on difficult-to-treat cancers, or related disorders, which have few, if any, treatment options.